We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The company will benefit from a landmark deal with the Trump Administration.
LLY exhibits robust fundamental and technical strength.
Eli Lilly Company Overview
Zacks Rank #1 (Strong Buy) Eli Lilly and Company ((LLY - Free Report) ) is one of the world’s largest and most diversified pharmaceutical companies. The Indiana, Indianapolis-based company offers a pharma product category that includez neuroscience (Cymbalta/Emgality), cardiometabolic health (Mounjaro, Zepbound, Trulicity, and others), oncology (Alimta, Cyramza, and Verzenio), immunology (Taltz, Omvoh, and Olumiant), and erectile dysfunction (Cialis). LLY has grown and continues to grow its business through key acquisitions, including Hypnion (a neuroscience drug discovery company focused on sleep disorders), CoLucid Pharmaceuticals (which offers acute migraine treatments), Loxo Oncology (which has cancer drugs), and several others. Additionally, Lill has collaboration agreements with several pharma companies, such as Incyte ((INCY - Free Report) ) and Roche ((RHHBY - Free Report) ).
Obesity: The Biggest Blockbuster Drugs Ever
One of the best pieces of advice that an entrepreneur can get is to solve problems. If an entrepreneur can solve a significant problem that a swath of people suffer from, the money will come. In the United States, no bigger problems exist than obesity and the adverse complications that come with it. In fact, according to the National Institute of Health (NIH), nearly 1 in 3 adults (30.7%) are overweight, and more than 2 in 5 adults (42.4%) have obesity.
Image Source: NIH
Mounjaro and Zepbound include the same compound, tirzepatide, a dual GIP and GLP-1 receptor agonist (GIP/GLP-1 RA). The GLP-1 segment is a very important class of drugs for multiple cardiometabolic diseases and is gaining significant popularity. Mounjaro was approved in May 2022 for the treatment of type II diabetes. Zepbound was launched in November 2023 for patients with obesity or overweight with weight-related comorbidities. Despite being on the market for such a short time, Mounjaro and Zepbound have become key top-line drivers for Lilly, with demand rising rapidly. Mounjaro and Zepbound generated combined sales of $16.5 billion in 2024, accounting for around 36% of the company’s total revenues.
Year to date, the drugs generated combined sales of $24.8 billion, comprising around 54% of the company’s total revenues. Launches of Mounjaro and Zepbound in new international markets and improved supply from ramped-up production in the United States have led to strong sales growth in 2025. The positive trend is expected to continue in 2026. Our estimates for Mounjaro and Zepbound suggest a CAGR of 44.6% and 73.7%, respectively, over the next three years. Meanwhile, in addition to Mounjaro and Zepbound, Lilly is investing broadly in obesity and has several new molecules currently in clinical development with a range of oral and injectable medications with different mechanisms of action.
Lilly Inks Obesity Drug Deal with Trump Administration
LLY has inked a deal with the Trump Administration to provide wider access to obesity drugs through the “TrumpRX” platform. The new “BALANCE” program will allow Medicare and Medicaid to cover GLP-1s for obesity with lower co-pays ($50/month) starting in 2027. These incentives should help to drive hot obesity drug sales even further.
New Drugs, Future Pipeline will Continue to Drive Growth
In addition to Mounjaro and Zepbound, Lilly has received approvals for other new drugs in the past couple of years. Omvoh/mirikizumab was approved for its first inflammatory bowel disease (IBD) indication, ulcerative colitis, in the United States, Europe and Japan in 2023 and for its second IBD condition, Crohn's disease, in the United States, Europe, and Japan in 2025. Additionally, Lilly has been building its pipeline and has a wide range of compounds in various stages of development.
Zacks Consensus Analyst Estimates expect robust EPS growth of 41.24% in 2026. LLY, which recently crossed the $1 trillion market cap landmark, will continue to attract institutional investors, as the company has the rare and coveted combination of rapid growth and underlying liquidity.
Image Source: Zacks Investment Research
LLY Bounces off the Rising 10-Week MA
Beyond fundamentals, LLY’s price action is also bullish. LLY shares are bouncing off the rising 10-week moving average for the first time since breaking out in late 2025, offering investors a high reward-to-risk entry point.
Image Source: TradingView
Bottom Line
Eli Lilly has solidified its position as a global pharma titan. With leading drugs and a massive obesity market, Lilly is poised to be a juggernaut for years to come.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Bull of the Day: Eli Lilly (LLY)
Key Takeaways
Eli Lilly Company Overview
Zacks Rank #1 (Strong Buy) Eli Lilly and Company ((LLY - Free Report) ) is one of the world’s largest and most diversified pharmaceutical companies. The Indiana, Indianapolis-based company offers a pharma product category that includez neuroscience (Cymbalta/Emgality), cardiometabolic health (Mounjaro, Zepbound, Trulicity, and others), oncology (Alimta, Cyramza, and Verzenio), immunology (Taltz, Omvoh, and Olumiant), and erectile dysfunction (Cialis). LLY has grown and continues to grow its business through key acquisitions, including Hypnion (a neuroscience drug discovery company focused on sleep disorders), CoLucid Pharmaceuticals (which offers acute migraine treatments), Loxo Oncology (which has cancer drugs), and several others. Additionally, Lill has collaboration agreements with several pharma companies, such as Incyte ((INCY - Free Report) ) and Roche ((RHHBY - Free Report) ).
Obesity: The Biggest Blockbuster Drugs Ever
One of the best pieces of advice that an entrepreneur can get is to solve problems. If an entrepreneur can solve a significant problem that a swath of people suffer from, the money will come. In the United States, no bigger problems exist than obesity and the adverse complications that come with it. In fact, according to the National Institute of Health (NIH), nearly 1 in 3 adults (30.7%) are overweight, and more than 2 in 5 adults (42.4%) have obesity.
Image Source: NIH
Mounjaro and Zepbound include the same compound, tirzepatide, a dual GIP and GLP-1 receptor agonist (GIP/GLP-1 RA). The GLP-1 segment is a very important class of drugs for multiple cardiometabolic diseases and is gaining significant popularity. Mounjaro was approved in May 2022 for the treatment of type II diabetes. Zepbound was launched in November 2023 for patients with obesity or overweight with weight-related comorbidities. Despite being on the market for such a short time, Mounjaro and Zepbound have become key top-line drivers for Lilly, with demand rising rapidly. Mounjaro and Zepbound generated combined sales of $16.5 billion in 2024, accounting for around 36% of the company’s total revenues.
Year to date, the drugs generated combined sales of $24.8 billion, comprising around 54% of the company’s total revenues. Launches of Mounjaro and Zepbound in new international markets and improved supply from ramped-up production in the United States have led to strong sales growth in 2025. The positive trend is expected to continue in 2026. Our estimates for Mounjaro and Zepbound suggest a CAGR of 44.6% and 73.7%, respectively, over the next three years. Meanwhile, in addition to Mounjaro and Zepbound, Lilly is investing broadly in obesity and has several new molecules currently in clinical development with a range of oral and injectable medications with different mechanisms of action.
Lilly Inks Obesity Drug Deal with Trump Administration
LLY has inked a deal with the Trump Administration to provide wider access to obesity drugs through the “TrumpRX” platform. The new “BALANCE” program will allow Medicare and Medicaid to cover GLP-1s for obesity with lower co-pays ($50/month) starting in 2027. These incentives should help to drive hot obesity drug sales even further.
New Drugs, Future Pipeline will Continue to Drive Growth
In addition to Mounjaro and Zepbound, Lilly has received approvals for other new drugs in the past couple of years. Omvoh/mirikizumab was approved for its first inflammatory bowel disease (IBD) indication, ulcerative colitis, in the United States, Europe and Japan in 2023 and for its second IBD condition, Crohn's disease, in the United States, Europe, and Japan in 2025. Additionally, Lilly has been building its pipeline and has a wide range of compounds in various stages of development.
Zacks Consensus Analyst Estimates expect robust EPS growth of 41.24% in 2026. LLY, which recently crossed the $1 trillion market cap landmark, will continue to attract institutional investors, as the company has the rare and coveted combination of rapid growth and underlying liquidity.
Image Source: Zacks Investment Research
LLY Bounces off the Rising 10-Week MA
Beyond fundamentals, LLY’s price action is also bullish. LLY shares are bouncing off the rising 10-week moving average for the first time since breaking out in late 2025, offering investors a high reward-to-risk entry point.
Image Source: TradingView
Bottom Line
Eli Lilly has solidified its position as a global pharma titan. With leading drugs and a massive obesity market, Lilly is poised to be a juggernaut for years to come.